Ranolazine: A new approach to treating an old problem

Texas Heart Institute Journal

Volumn 37, Issue 6, 2010, Pages 641-647

  Reddy, Bharath M ^a   Weintraub, Howard S ^a   Schwartzbard, Arthur Z ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angina pectoris drug therapy prevention; Anti arrhythmia agents pharmacology therapeutic use; Cardiovascular agents pharmacology therapeutic use; Clinical trials as topic; Control; Coronary disease drug therapy; Dosage; Dose response relationship; Drug; Heart conduction system drug effects metabolism physiopathology; Myocardial ischemia drug therapy; Piperazines therapeutic use; Ranolazine administration ; Sodium channel blockers pharmacology therapeutic use; Sodium channels drug effects metabolism physiology

Indexed keywords

DIGOXIN; DILTIAZEM; HEMOGLOBIN A1C; KETOCONAZOLE; PLACEBO; RANOLAZINE; SIMVASTATIN; SODIUM CHANNEL; VERAPAMIL;

ACUTE CORONARY SYNDROME; ASTHENIA; CONSTIPATION; DIASTOLIC HEART FAILURE; DIZZINESS; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG EXCRETION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; FATTY ACID OXIDATION; GLYCEMIC CONTROL; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; NAUSEA; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERIPHERAL EDEMA; REVIEW; STABLE ANGINA PECTORIS; TREATMENT INDICATION; UNSTABLE ANGINA PECTORIS;

ACETANILIDES; ANGINA PECTORIS; ANGINA, UNSTABLE; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CHRONIC DISEASE; EVIDENCE-BASED MEDICINE; HEART DISEASES; HEART FAILURE, DIASTOLIC; HUMANS; MYOCARDIAL INFARCTION; PIPERAZINES; PRACTICE GUIDELINES AS TOPIC; SODIUM CHANNEL BLOCKERS; TREATMENT OUTCOME;

EID: 79251480748     PISSN: 07302347     EISSN: 15266702     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Fraker TD Jr, Fihn SD, 2002 Chronic Stable Angina Writing Committee, American College of Cardiology, American Heart Association, Gibbons RJ, et al. 2007 chronic angina focused update f the ACC/AHA 2002 guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to develop the focused update of the 2002 guidelines for the management of patients with chronic stable angina [published erratum appears in e1]. J Am Coll Cardiol 2007;50(23):2264-2274.
2. Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007;356 (15):1503-16.
3. Zaza A, Belardinelli L, Shryock JC. Pathophysiology and pharmacology of the cardiac "late sodium current." Pharmacol Ther 2008;119(3):326-339.
4. Stone PH. Ranolazine: new paradigm for management of myocardial ischemia, myocardial dysfunction, and arrhythmias. Cardiol Clin 2008;26(4):603-614.
5. Noble D, Noble PJ. Late sodium current in the pathophysiology of cardiovascular disease: consequences of sodium-calcium overload. Heart 2006;92 Suppl 4:41-45.
6. Le Grand B, Pignier C, Letienne R, Colpaert F, Cuisiat F, Rolland F, et al. Na+ currents in cardioprotection: better to be late. J Med Chem 2009;52(14):4149-4160.
7. Hale SL, Shryock JC, Belardinelli L, Sweeney M, Kloner RA. Late sodium current inhibition as a new cardioprotective approach. J Mol Cell Cardiol 2008;44(6):954-967.
8. Saint DA. The cardiac persistent sodium current: an appealing therapeutic target? Br J Pharmacol 2008;153(6):1133-1142.
9. Hayashida W, van Eyll C, Rousseau MF, Pouleur H. Effects of ranolazine on left ventricular egional diastolic function in patients with ischemic heart disease. Cardiovasc Drugs Ther 1994;8(5):741-747.
10. MacInnes A, Fairman DA, Binding P, Rhodes J, Wyatt MJ, Phelan A, et al. The antianginal agent trimetazidine does not exert its functional benefit via inhibition of mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 2003;93 (3):e26-32.
11. Antzelevitch C, Belardinelli L, Zygmunt AC, Burashnikov A, Di Diego JM, Fish JM, et al. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation 2004;110(8):904-910.
12. Fraser H, Belardinelli L, Wang L, Light PE, McVeigh JJ, Clanachan AS. Ranolazine decreases diastolic calcium accumulation caused by ATX-II or ischemia in rat hearts. J Mol Cell Cardiol 2006;41(6):1031-1038.
13. Ranexa® dosing information [cited 2010 Nov 1]. Available at: http://www.ranexa.com/HCP/Dosing/Default.aspx Nash DT, Nash SD. Ranolazine for chronic stable angina. Lancet 2008;372(9646):1335-1341.
14. Pepine CJ, Wolff AA. A controlled trial with a novel anti-ischemic agent, ranolazine, in chronic stable angina pectoris that is responsive to conventional antianginal agents. Ranolazine Study Group. Am J Cardiol 1999;84(1):46-50.
15. Chaitman BR, Skettino SL, Parker JO, Hanley P, Meluzin J, Kuch J, et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol 2004;43(8):1375-182.
16. Chaitman BR, Pepine CJ, Parker JO, Sokpal J, Chumakova G, Kuch J, et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA 2004;291(3):309-316.
17. Stone PH, Gratsiansky NA, Blokhin A, Huang IZ, Meng L; ERICA Investigators. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol 2006;48(3):566-575.
18. Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, Murphy SA, Budaj A, Varshavsky S, et al. Effects of ranolazine on recurrent cardiovascular events in patients with non-STelevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. JAMA 2007;297(16):1775-1783.
19. Morrow DA, Scirica BM, Chaitman BR, McGuire DK, Murphy SA, Karwatowska-Prokopczuk E, et al. Evaluation of the glycometabolic effects of ranolazine in patients with and without diabetes mellitus in the MERLIN-TIMI 36 randomized controlled trial. Circulation 2009;119(15):2032-2039.
20. Wilson SR, Scirica BM, Braunwald E, Murphy SA, Karwatowska-Prokopczuk E, Buros JL, et al. Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial. J Am Coll Cardiol 2009;53(17):1510-1516.
21. Venkataraman R, Belardinelli L, Blackburn B, Heo J, Iskandrian AE. A study of the effects of ranolazine using automated quantitative analysis of serial myocardial perfusion images. JACC Cardiovasc Imaging 2009;2(11):1301-1309.
22. Mega JL, Hochman JS, Scirica BM, Murphy SA, Sloan S, McCabe CH, et al. Clinical features and outcomes of women with unstable ischemic heart disease: observations from metabolic eff iciency with ranolazine for less ischemia in non-ST-elevation acute coronary syndromes-thrombolysis in myocardial infarction 36 (MERLIN-TIMI 36). Circulation 2010;121(16):1809-1817.
23. Schram G, Zhang L, Derakhchan K, Ehrlich JR, Belardinelli L, Nattel S. Ranolazine: ion-channel-blocking actions and in vivo electrophysiological effects. Br J Pharmacol 2004;142(8): 1300-1308.
24. Chaitman BR. Efficacy and safety of a metabolic modulator drug in chronic stable angina: review of evidence from clinical trials. J Cardiovasc Pharmacol Ther 2004;9 Suppl 1:S47-64.
25. Scirica BM, Morrow DA, Hod H, Murphy SA, Belardinelli L, Hedgepeth CM, et al. Effect of ranolazine, an antianginalagent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency with Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation 2007;116(15):1647-1652.
26. Burashnikov A, Antzelevitch C. Atrial-selective sodium channel block for the treatment of atrial fibrillation. Expert Opin Emerg Drugs 2009;14(2):233-249.
27. Burashnikov A, Antzelevitch C. Atrial-selective sodium channel blockers: do they exist? J Cardiovasc Pharmacol 2008;52 (2):121-128.
28. Dobrev D. Cardiomyocyte Ca2+ overload in atrial tachycardia: is blockade of L-type Ca2+ channels a promising approach to prevent electrical remodeling and arrhythmogenesis? Naunyn Schmiedebergs Arch Pharmacol 2007;376(4):227-230.
29. Song Y, Shryock JC, Belardinelli L. An increase of late sodium current induces delayed afterdepolarizations and sustained triggered activity in atrial myocytes. Am J Physiol Heart Circ Physiol 2008;294(5):H2031-2039.
30. Burashnikov A, Di Diego JM, Zygmunt AC, Belardinelli L, Antzelevitch C. Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine. Circulation 2007;116(13):1449-1457.
31. Sicouri S, Glass A, Belardinelli L, Antzelevitch C. Antiarrhythmic effects of ranolazine in canine pulmonary vein sleeve preparations. Heart Rhythm 2008;5(7):1019-1026.
32. Murdock DK, Overton N, Kersten M, Kaliebe J, Devecchi F. The effect of ranolazine on maintaining sinus rhythm in patients with resistant atrial fibrillation. Indian Pacing Electrophysiol J 2008;8(3):175-181.
33. Ver Donck L, Borgers M, Verdonck F. Inhibition of sodium and calcium overload pathology in the myocardium: a new cytoprotective principle. Cardiovasc Res 1993;27(3):349-357.
34. Undrovinas AI, Belardinelli L, Undrovinas NA, Sabbah HN. Ranolazine improves abnormal repolarization and contraction in left ventricular myocytes of dogs with heart failure by inhibiting late sodium current. J Cardiovasc Electrophysiol 2006;17 Suppl 1:S169-S177.
35. Sossalla S, Wagner S, Rasenack EC, Ruff H, Weber SL, Schondube FA, et al. Ranolazine improves diastolic dysfunction in isolated myocardium from failing human hearts-role of late sodium current and intracellular ion accumulation. J Mol Cell Cardiol 2008;45(1):32-43.
36. Morrow DA, Scirica BM, Sabatine MS, de Lemos JA, Murphy SA, Jarolim P, et al. B-type natriuretic peptide and the effect of ranolazine in patients with non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 (Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary-Thrombolysis In Myocardial Infarction 36) trial. J Am Coll Cardiol 2010;55(12): 1189-1196.
37. Timmis AD, Chaitman BR, Crager M. Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes. Eur Heart J 2006;27(1):42-48.
38. Deshmukh SH, Patel SR, Pinassi E, Mindrescu C, Hermance EV, Infantino MN, et al. Ranolazine improves endothelial function in patients with stable coronary artery disease. Coron Artery Dis 2009;20(5):343-347.